Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PELITREXOL/AG-2037 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| PELITREXOL/AG-2037 | DRUG | - |
Inclusion Criteria: * Histologically or cytologically confirmed metastatic adenocarcinoma of the colon or rectum * Stage IV or recurrent disease * Measurable disease * Disease progression or recurrence during or after completion of prior first-line chemotherapy with fluorouracil and leucovorin calc...
PELITREXOL/AG-2037 is an investigational small molecule developed by Pfizer, Inc. (ticker: PFE) for the treatment of colorectal neoplasms. It is a GART inhibitor that has been studied in patients with metastatic colorectal cancer. The drug remains in clinical development and is not approved for commercial use.
PELITREXOL/AG-2037 has been studied for colorectal neoplasms, specifically in patients with metastatic colorectal cancer who failed prior treatment. Its only recorded clinical trial enrolled adults with this condition. The asset is investigational and has not been approved for any indication.
PELITREXOL/AG-2037 targets GART, also known as glycinamide ribonucleotide transformylase. It acts as an inhibitor of this enzyme. GART is involved in purine biosynthesis, and inhibiting it is the intended mechanism of action for this small molecule in colorectal cancer research.
Pfizer, Inc. is the developer of PELITREXOL/AG-2037. The company trades under the ticker PFE. Pfizer holds the asset, which is a small molecule GART inhibitor being investigated in oncology, specifically for colorectal neoplasms.
PELITREXOL/AG-2037 is in Phase 2 development. Its single recorded trial, NCT00078468, was a Phase 2 study in metastatic colorectal cancer that has completed. The drug is investigational and has not received FDA approval for any indication.
PELITREXOL/AG-2037 has been evaluated in one clinical trial, NCT00078468, titled a study of the GARFT inhibitor AG2037 in patients with metastatic colorectal cancer who failed treatment. The Phase 2 trial enrolled 56 patients in the United States and is completed. It was an uncontrolled study without randomization or blinding.